Second-Line Treatments for Metastatic Melanoma

Opinion
Video

Insights about second-line treatment options for metastatic melanoma and discusses available data for treatment sequencing.

Case: A 62-Year-Old Female with Stage IV Melanoma

  • A 62-year-old female consulted with her dermatologist for removal of a pigmented lesion that had recently become darker.
    • She noted that she had been experiencing persistent fatigue, shortness of breath, and a dry cough that she attributed to a prior COVID-19 infection.
    • LDH: 174 UI/L
  • Excisional biopsy reveals melanoma with a Breslow depth of 1.2 mm, ulcerated, mitotic rate 4/mm2
    • The patient underwent wide local excision and sentinel node mapping
    • Staining was positive for melanoma in the right axillary node
    • CT of the chest, abdomen, and pelvis indicated multiple lesions in both lungs
    • The patient underwent core-needle biopsy of the largest lung lesion, measuring 1 cm
    • Pathology revealed metastatic melanoma, cutaneous nonacral with a positive BRAF V600E mutation
    • ECOG PS 1
  • Diagnosis: Stage IV Melanoma, T2b N1a M1b

This is a video synopsis/summary of a Case-Based Peer Perspective, featuring Michael B. Atkins, MD.

For this patient progressing after first-line nivolumab plus ipilimumab, next treatment would undoubtedly be a BRAF/MEK inhibitor combination. The improved outcomes with immunotherapy first in the DREAMseq trial (NCT02224781) relate to 3 key factors: (1) longer duration of response to immunotherapy; (2) more CNS progressions on targeted therapy; and (3) BRAF/MEK inhibitors retain efficacy second-line after immunotherapy progression, whereas second-line immunotherapy is less effective following targeted therapy.

Targeted therapy is a critical component of the optimal treatment sequence following initial immunotherapy. BRAF/MEK inhibitors work as well second line as first line, overcoming the relatively poor second-line immunotherapy responses after disease progression on targeted therapy.

Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.

Recent Videos
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Solly Chedid, MD, an expert on MDS
Related Content